These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 22833259)

  • 1. Sorafenib reduces hepatic infiltrated regulatory T cells in hepatocellular carcinoma patients by suppressing TGF-beta signal.
    Wang Q; Yu T; Yuan Y; Zhuang H; Wang Z; Liu X; Feng M
    J Surg Oncol; 2013 Mar; 107(4):422-7. PubMed ID: 22833259
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Upregulation of HIF-2α induced by sorafenib contributes to the resistance by activating the TGF-α/EGFR pathway in hepatocellular carcinoma cells.
    Zhao D; Zhai B; He C; Tan G; Jiang X; Pan S; Dong X; Wei Z; Ma L; Qiao H; Jiang H; Sun X
    Cell Signal; 2014 May; 26(5):1030-9. PubMed ID: 24486412
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sorafenib inhibits hypoxia-inducible factor-1α synthesis: implications for antiangiogenic activity in hepatocellular carcinoma.
    Liu LP; Ho RL; Chen GG; Lai PB
    Clin Cancer Res; 2012 Oct; 18(20):5662-71. PubMed ID: 22929805
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Down-Regulation of TGF-β Expression Sensitizes the Resistance of Hepatocellular Carcinoma Cells to Sorafenib.
    Kang D; Han Z; Oh GH; Joo Y; Choi HJ; Song JJ
    Yonsei Med J; 2017 Sep; 58(5):899-909. PubMed ID: 28792132
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sorafenib down-regulates expression of HTATIP2 to promote invasiveness and metastasis of orthotopic hepatocellular carcinoma tumors in mice.
    Zhang W; Sun HC; Wang WQ; Zhang QB; Zhuang PY; Xiong YQ; Zhu XD; Xu HX; Kong LQ; Wu WZ; Wang L; Song TQ; Li Q; Tang ZY
    Gastroenterology; 2012 Dec; 143(6):1641-1649.e5. PubMed ID: 22922424
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sorafenib relieves cell-intrinsic and cell-extrinsic inhibitions of effector T cells in tumor microenvironment to augment antitumor immunity.
    Chen ML; Yan BS; Lu WC; Chen MH; Yu SL; Yang PC; Cheng AL
    Int J Cancer; 2014 Jan; 134(2):319-31. PubMed ID: 23818246
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MiR-101 targets DUSP1 to regulate the TGF-β secretion in sorafenib inhibits macrophage-induced growth of hepatocarcinoma.
    Wei X; Tang C; Lu X; Liu R; Zhou M; He D; Zheng D; Sun C; Wu Z
    Oncotarget; 2015 Jul; 6(21):18389-405. PubMed ID: 26158762
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor-Associated Neutrophils Recruit Macrophages and T-Regulatory Cells to Promote Progression of Hepatocellular Carcinoma and Resistance to Sorafenib.
    Zhou SL; Zhou ZJ; Hu ZQ; Huang XW; Wang Z; Chen EB; Fan J; Cao Y; Dai Z; Zhou J
    Gastroenterology; 2016 Jun; 150(7):1646-1658.e17. PubMed ID: 26924089
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Heterogeneous sensitivity of hepatocellular carcinoma to sorafenib revealed by the short-term culture of tumor fragments.
    Godin C; Dupont S; Ezzoukhry Z; Louandre C; Chatelain D; Henaut L; Sabbagh C; Regimbeau JM; Maziere JC; Barbare JC; Chauffert B; Galmiche A
    Anticancer Res; 2013 Apr; 33(4):1415-20. PubMed ID: 23564781
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exosomes derived from HCC cells induce sorafenib resistance in hepatocellular carcinoma both in vivo and in vitro.
    Qu Z; Wu J; Wu J; Luo D; Jiang C; Ding Y
    J Exp Clin Cancer Res; 2016 Sep; 35(1):159. PubMed ID: 27716356
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Validation of VX2 as a Hepatocellular Carcinoma Model: Comparison of the Molecular Reaction of VX2 and HepG2 Tumor Cells to Sorafenib In Vitro.
    Nass N; Streit S; Wybranski C; Jürgens J; Brauner J; Schulz N; Powerski M; Ricke J; Kalinski T; Dudeck O; Seidensticker M
    Anticancer Res; 2017 Jan; 37(1):87-93. PubMed ID: 28011478
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MicroRNA-122 confers sorafenib resistance to hepatocellular carcinoma cells by targeting IGF-1R to regulate RAS/RAF/ERK signaling pathways.
    Xu Y; Huang J; Ma L; Shan J; Shen J; Yang Z; Liu L; Luo Y; Yao C; Qian C
    Cancer Lett; 2016 Feb; 371(2):171-81. PubMed ID: 26655273
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sorafenib enhances the chemotherapeutic efficacy of S-1 against hepatocellular carcinoma through downregulation of transcription factor E2F-1.
    Zhai JM; Yin XY; Lai YR; Hou X; Cai JP; Hao XY; Liang LJ; Zhang LJ
    Cancer Chemother Pharmacol; 2013 May; 71(5):1255-64. PubMed ID: 23435877
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nuclear factor kappa B-mediated CD47 up-regulation promotes sorafenib resistance and its blockade synergizes the effect of sorafenib in hepatocellular carcinoma in mice.
    Lo J; Lau EY; Ching RH; Cheng BY; Ma MK; Ng IO; Lee TK
    Hepatology; 2015 Aug; 62(2):534-45. PubMed ID: 25902734
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pathways and targets in hepatocellular carcinoma.
    Psyrri A; Arkadopoulos N; Vassilakopoulou M; Smyrniotis V; Dimitriadis G
    Expert Rev Anticancer Ther; 2012 Oct; 12(10):1347-57. PubMed ID: 23176622
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synergistic effects of β-catenin inhibitors and sorafenib in hepatoma cells.
    Muche S; Kirschnick M; Schwarz M; Braeuning A
    Anticancer Res; 2014 Sep; 34(9):4677-83. PubMed ID: 25202044
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MicroRNA-216a/217-induced epithelial-mesenchymal transition targets PTEN and SMAD7 to promote drug resistance and recurrence of liver cancer.
    Xia H; Ooi LL; Hui KM
    Hepatology; 2013 Aug; 58(2):629-41. PubMed ID: 23471579
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sorafenib increases efficacy of vorinostat against human hepatocellular carcinoma through transduction inhibition of vorinostat-induced ERK/NF-κB signaling.
    Hsu FT; Liu YC; Chiang IT; Liu RS; Wang HE; Lin WJ; Hwang JJ
    Int J Oncol; 2014 Jul; 45(1):177-88. PubMed ID: 24807012
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The retinoblastoma (Rb) protein regulates ferroptosis induced by sorafenib in human hepatocellular carcinoma cells.
    Louandre C; Marcq I; Bouhlal H; Lachaier E; Godin C; Saidak Z; François C; Chatelain D; Debuysscher V; Barbare JC; Chauffert B; Galmiche A
    Cancer Lett; 2015 Jan; 356(2 Pt B):971-7. PubMed ID: 25444922
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metformin sensitizes sorafenib to inhibit postoperative recurrence and metastasis of hepatocellular carcinoma in orthotopic mouse models.
    You A; Cao M; Guo Z; Zuo B; Gao J; Zhou H; Li H; Cui Y; Fang F; Zhang W; Song T; Li Q; Zhu X; Yin H; Sun H; Zhang T
    J Hematol Oncol; 2016 Mar; 9():20. PubMed ID: 26957312
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.